Introducing a targeted,
potent, immune-balancing therapeutic.
Introducing a targeted,
potent, immune-balancing therapeutic.
The Science
By isolating the active portion of AAT, we’ve created a small, selective, and highly-potent therapeutic called SP16.
When SP16 activates LRP1, it resolves inflammation in three important ways:
1. Harmful inflammatory triggers are removed from the cell surface.
2. Key survival pathways such as ERK and AKT become activated, increasing cell resilience.
3. And pro-inflammatory pathways
like NFkB become deactivated,
thereby balancing cytokine output.
What Makes SP16 a Breakthrough Solution?
When the body’s immune response is activated due to disease or injury, inflammation is produced to eliminate the threat. However, too much inflammation can harm the body’s own cells, inducing further damage and distress. Current therapies (including cytokine blockers and steroids) focus on reducing this inflammation, yet in doing so they inhibit the body’s natural immune response, which is essential for complete healing.
Serpin Pharma identified the need for an anti-inflammatory therapeutic that works with, not against, the body’s innate immune response.
By improving on a naturally occurring immunomodulatory protein and targeting a receptor that restores homeostasis to the cell, Serpin Pharma has created a therapeutic that is targeted, potent, and immune balancing.
Our therapeutic, known as SP16, stimulates the body’s innate mechanism for inflammation management. When SP16 binds to the homeostatic receptor LRP1, harmful molecules and pathogens are cleared from the cell surface, and pathways associated with inflammation and cell death become less active. As a result, treatment with SP16 reduces the progression of inflammation before it can reach dangerous levels, such as the “cytokine storm” that has been observed in critical COVID-19 patients. Not only does SP16 prevent cell death, but it actively works towards cell and tissue repair by promoting key proliferative/protective pathways (such as ERK/AKT). In this way, SP16 represents a new class of therapeutics for the treatment of inflammatory diseases.
Our Research Story
In the past few decades, scientists have grown increasingly interested in the therapeutic potential of Serine Protease Inhibitors (SERPINs). Most studies have focused on their anti-protease activity. However, at Serpin Pharma, we were uniquely interested in the SERPINs’ anti-inflammatory and immunoregulatory properties.
We developed SP16 from a classic SERPIN protein called AAT, which is known to be involved in reducing inflammation as well as promoting wound healing and tissue repair. To improve on AAT’s anti-inflammatory activity, we selectively removed portions of the molecule responsible for protease inhibition, as well as those involved in promoting inflammation.
The result? A small, highly selective, peptide therapeutic that is 300 times more potent than its natural counterpart.
Other advantages of SP16 are its safety; moreover, it is not isolated from plasma, which also makes it highly cost-effective to produce. Clinical trials thus far have shown no off-target effects associated with SP16 treatment.
Serpin Pharma currently holds thirteen strong patents concerning the Composition of Matter and Method of Use for its pipeline technologies.
Copyright © Serpin Pharma,
LLC 2022 - All Rights Reserved
